Contrario Medical, Inc. appears in FDA 510(k) records as the applicant for Cyperus, a Class II device reviewed under the Obstetrics/Gynecology advisory committee. The submission was received on 6 July 2026 and decided on 26 October 2026 with a substantially equivalent decision, according to FDA records linked by MedtechLedger. The record identifies a traditional clearance type, a summary statement, and no third-party review. The applicant contact listed is Albert Huang, with a Houston, Texas address on the filing. That address is a filing detail, not a verified headquarters. [1][2][5][7]
The Cyperus clearance and its classification
K262276 covers a device named Cyperus, classified under product code MQK and regulation 21 CFR 884.6160, whose classification name is Labware, Assisted Reproduction. FDA assigned device class 2 and routed review to the Obstetrics/Gynecology panel. The decision code is SESE, described as Substantially Equivalent, dated 26 October 2026. The submission is listed as Traditional, not reviewed by a third party, and not a combination product. A summary statement was prepared for the filing. [1][2][5][6]
Independent indexes of the same FDA data reach the same classification: Innolitics places K262276 under Subpart G, Assisted Reproduction Devices, and FDA.report lists the same product code, regulation, specialty and decision date. These are secondary renderings of public FDA datasets, not separate regulatory actions. [5][6]
Submission timeline
FDA records show the application received on 6 July 2026 and decided on 26 October 2026, a span of roughly three and a half months. The 510(k) final-decision listings published for the weeks of 11 and 16 November 2026 both include K262276 with a Substantially Equivalent decision and Contrario Medical, Inc. as applicant. The FDA premarket notification page for the record was last updated 9 November 2026. [1][2][3][4][7]
The filing is the only 510(k) in the linked record set for this applicant. That count reflects the records retrieved as of 20 November 2026 and is not a statement about the company's total regulatory history, product portfolio or commercial activity. [1][8]
What the public record does and does not establish
The FDA record documents an applicant name, a device name, a classification, a review pathway and a decision. It does not document ownership, parent companies, brand relationships, manufacturing sites, customers, pricing or commercial availability. The Houston address and contact name appear as filing details in the FDA data; they should not be read as a verified corporate headquarters or as confirmation of where the device is made. [1][5][8]
A third-party index describes the clearance as the start of commercialization activity, but that is the publisher's interpretation of an approval signal, not a fact established by FDA. No source here confirms distribution, reimbursement, sales staffing or clinical use of Cyperus. [8]
Reading the record alongside other clearances
The same FDA decision listings that include K262276 also include unrelated clearances decided on 26 October 2026, such as K262567 for GPS Ankle (Blue Ortho) and K260285 for Triad Hydrophilic Wound Dressing (Coloplast Corp.). Their presence in the same weekly feed reflects shared publication timing, not any relationship to Contrario Medical. [3][4]
For industry readers tracking assisted-reproduction labware, K262276 is a dated, verifiable data point: a Class II, product code MQK clearance with a Traditional review and a summary statement. Anything beyond that, including performance claims or market position, is outside what these records show. [1][2][6]

